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Background
Four previously published trials assessed the efficacy of
MP29-02* (a novel intranasal formulation of azelastine
hydrochloride (AZE) and fluticasone propionate (FP) in an
advanced delivery system) in seasonal allergic rhinitis
(SAR) [1,2]. The first study compared MP29-02* to mar-
keted AZE and FP [2]. The others compared MP29-02* to
AZE and FP in the MP29-02* vehicle and delivery device
(i.e. re-formulated comparators) [1]. FP contained within
MP29-02* has a unique PK fingerprint [3]. The aim of this
analysis was to demonstrate that formulation/device con-
tribute to MP29-02*’s clinical efficacy.
Methods
Four thousand and five moderate/severe SAR patients
(≥12 yrs old) were randomized into 4 double-blind, pla-
cebo (PLA)-controlled trials. Each trial comprised 4 groups:
MP29-02*, AZE, FP and PLA nasal sprays, and was con-
ducted for 14 days. Total daily dose of AZE and FP were
548 µg and 200 µg, respectively. Change from baseline
(CFB) in reflective total nasal symptom score (rTNSS)
over 14-days was the primary outcome. CFB in reflective
total ocular symptom score (rTOSS) and individual nasal
and ocular symptoms was assessed secondarily. Time to
achieve at least a 50% rTNSS reduction from baseline was
assessed post-hoc by Kaplan Meier estimates and log rank
tests. The formulation/device effect of MP29-02* was
quantified by comparing treatment differences obtained
with MP29-02* vs marketed FP and MP29-02* vs re-
formulated FP for these endpoints.
Results
For all efficacy variables assessed, the treatment difference
was greater for MP29-02* vs marketed-FP than for MP29-
02* vs re-formulated-FP. For rTNSS, the difference
between MP29-02* and marketed-FP was -1.47, compared
to -0.76 vs reformulated-FP; a formulation/device effect of
0.71. Similarly for rTOSS a formulation/device effect of
0.70 was observed. A formulation/device effect was
observed for relief of all individual nasal and ocular symp-
toms (e.g. 0.23 effect for congestion; 0.34 effect for ocular
itching). Finally, MP29-02*-patients achieved a ≥50%
rTNSS reduction ≤6 days faster than marketed-FP and ≤3
days faster than reformulated-FP, a formulation/device
effect of ≤3 days.
Conclusion
Formulation and device contribute to MP29-02*’s superior
efficacy over currently considered firstline therapy, making
MP29-02* a new class of treatment for AR.
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